Lewis Lung Carcinoma Mouse Model: LL/2
Lung cancer is the leading cause of death from cancer related illness. Annually, over 140,000 people die from lung cancer in the United States, with a five-year survival rate under 20%.
LL/2 is a mouse Lewis lung carcinoma, originally derived from a spontaneous epidermoid carcinoma in a C57BL mouse in 1951. LL/2 has extensive applications as a syngeneic tumor model for immunotherapies.
Metastatic potential
This cell line is highly tumorigenic but weakly metastatic in mice. Subcutaneous implantation methods in C57BL mice have shown subcutaneous tumor formation along with limited lung metastases.
Immunogenicity
This tumor type is unlikely to trigger a T-cell immune response, an advantageous characteristic for developing treatments for patients unresponsive to contemporary immuno-oncology methodologies.
Fully Characterized Model
LL/2 cells can be used in both orthotopic (lung) or syngeneic (flank) models.
Lewis Lung Carcinoma LL/2 (LLC1) Model
LL/2 model is well suited for orthotopic and flank syngeneic models.